It is well established that ER expression level is a determinant of tamoxifen response in ER+ breast cancer, and loss of ER expression is a crucial factor contributing to tamoxifen resistance (Musgrove & Sutherland, 2009; Osborne & Schiff, 2011). Here, ESR1 is linked to breast carcinoma.